If Klaviyo shut your account, it wasn’t a glitch, and an appeal with a softer description of your catalog won’t fix it. Peptide email marketing has to start from a fact most founders learn the hard way: we couldn’t find a single email platform that publicly says it accepts research peptides.
That doesn’t mean you can’t run email. It means you pick a platform by reading its acceptable use policy and asking in writing, you keep your list in a form you can move in an afternoon, and you send the kind of email that doesn’t give a compliance reviewer, or a regulator, anything to work with.
We’re not going to name a “peptide-friendly” platform, because no policy we’ve read supports that label. What we can do is show you what the policies say, how to check one yourself, and three abandoned cart email examples that recover sales without a single claim.
Why email platforms shut down peptide senders
An email platform carries risk for what’s sent from its infrastructure. Its sending reputation is shared across customers, and its own payment and banking partners care about what it hosts. So every platform has an acceptable use policy (AUP) with a list of prohibited or restricted products, and almost every AUP reserves the right to decide what falls inside those categories.
Klaviyo’s acceptable use policy (updated Apr 9, 2026) says under Prohibited Content: “You may not use the Services to offer products or services related to: Prescription medications, pharmaceutical products or services, medical therapies, telehealth…” It also lists CBD, kratom and THC. The words “peptides” and “supplements” don’t appear.
So Klaviyo’s policy doesn’t name peptides. But “pharmaceutical products” is a broad phrase, and a reviewer looking at a catalog of compounds that LegitScript describes as illegal to market for human consumption without FDA approval doesn’t need the word “peptide” in the policy to make a call. If your emails or site also carry dosing content or effect claims, the call is easy.
What email platform policies actually say about peptides
Here’s what each policy we checked says, as of 2026. Read the current version yourself before you rely on any of it; the dates show how often these change.
| Platform | Policy date | What it says | What that means for a research peptide sender |
|---|---|---|---|
| Klaviyo | Updated Apr 9, 2026 | Prohibits offering products related to “Prescription medications, pharmaceutical products or services, medical therapies, telehealth”; peptides and supplements not named | Not named, but the categories are broad and enforcement is discretionary |
| Mailchimp | Updated Sep 26, 2025 | “May not allow businesses that offer” “Pharmaceutical products”; nutritional, herbal and vitamin supplements get closer review | Same broad category; expect scrutiny |
| Omnisend | Updated Apr 30, 2026 | Prohibits prescription medications “including but not limited to drugs for research purposes” | The most explicit ban on research products we found |
| ActiveCampaign | Effective Mar 1, 2022 | Restricts drugs “whether available only by prescription or over-the-counter” and products claiming “to diagnose, cure, treat, or prevent a disease”; dietary supplements allowed only to US contacts | Restrictive wording on drugs and disease claims |
| Elastic Email | Oct 30, 2024 | Lists “pharmaceuticals” as prohibited | Broad category, discretionary |
| Amazon SES (AWS) | AUP dated Jul 1, 2021 | No industry list; prohibits illegal or fraudulent use and spam | Policy is silent on categories; account review is discretionary, and whether it approves peptide senders in practice is unknown |
| Sendlane | Not retrievable | We couldn’t access the AUP | Unknown; ask |
| Mautic | Self-hosted | No vendor content policy | The policy of whatever SMTP relay you send through applies instead |
The Omnisend line is worth reading in full on its acceptable use policy page. If your catalog is research peptides, that’s about as clear a no as these documents get.
How to check an email platform before you migrate
This is the process we run for clients before moving a list anywhere:
- Read the whole AUP, plus any separate “prohibited industries” or “restricted content” page. Note the date at the top.
- Search the text for: pharmaceutical, drug, research, chemical, supplement, prescription, health. Read every sentence those words appear in.
- Check the infrastructure underneath. If the tool sends through a third-party relay, that relay’s AUP applies too. With self-hosted software, the relay is the only policy that matters.
- Ask in writing. Open a ticket with the platform’s compliance or support team. Describe the business exactly as it is: what you sell, how it’s labeled, your website URL, roughly how many contacts and sends a month. Ask: “Is this permitted under your acceptable use policy?” Save the reply.
- Make sure your site would pass their look. Reviewers click through to your website. If it has dosing content, reconstitution calculators or effect claims, the answer to step 4 won’t matter for long.
- Set a reminder to re-read the AUP every quarter and whenever the platform emails you about policy changes.
Two cautions. A written “yes” from a support agent is better than nothing, but most AUPs reserve discretion, so it isn’t a guarantee. And describing your business as something it isn’t to get approved (“we sell lab supplies”) is the email version of miscoding a merchant account. It ends the same way, usually with your list frozen mid-campaign. We don’t help with that, and we’d talk you out of it.
Own your list before you need to move it
The real damage from a ban is rarely the platform. It’s losing the list, the consent records and the flows all at once. Set this up now, while you still have access:
- Export weekly. Contacts, consent status, consent timestamp and source, unsubscribes, bounces and the suppression list. Store the files outside the email platform.
- Use double opt-in. It gives you a timestamped consent record for every contact, which is what a new platform will ask about when you import.
- Keep your sign-up form wording on file, with the date it changed. Consent is only as good as what the subscriber agreed to.
- Carry the suppression list over. Re-mailing people who unsubscribed is a legal problem and a deliverability problem at the same time.
- Document your flows outside the tool. Welcome series, restock alerts, post-purchase: trigger, timing, subject lines, and the HTML of each email.
- Never import a bought or scraped list. It’s the fastest way to get suspended by a new platform in week one.
Deliverability basics on a new platform
Moving platforms resets more than people expect. Do these before the first send:
- Send from your own domain, ideally a subdomain such as news.yourbrand.com, never the platform’s shared sending domain.
- Set up SPF, DKIM and DMARC for that domain. Start DMARC at p=none with reporting turned on, read the reports, then tighten it.
- Meet the Gmail and Yahoo bulk-sender rules in place since 2024: authenticated mail, one-click unsubscribe and low spam complaint rates.
- Warm up gradually. Start with your most engaged recent subscribers and raise volume over a few weeks, rather than blasting the whole list on day one.
- Separate transactional email from marketing. Order confirmations and shipping notices should go through your store platform or a separate provider, so a marketing ban never stops customers hearing about their orders.
- Sunset unengaged contacts on a schedule. Old addresses drag down the reputation of everything else you send.
What to send that stays compliant
FDA can establish a product’s intended use from “labeling claims, advertising matter, or oral or written statements,” under 21 CFR 201.128. Your emails are advertising matter. They get read the same way your product pages do.
What we’d send:
- Restock notices, with the lot number
- New batch announcements with the COA linked (our post on publishing peptide lab testing results covers what that page should hold)
- Shipping cut-offs, holiday delays and changes to the regions you ship to
- New SKUs, described by specs: amount per vial, format, storage
- Price changes and policy updates
- Changes to your testing lab or testing protocol
What we’d never send: dosing or “protocol” content, reconstitution guides or calculators, effect or benefit claims, before-and-after stories, customer testimonials about results, bodybuilding or tanning angles, and bacteriostatic water promoted alongside peptides. FDA’s August 2026 warning letters to peptide sellers cited exactly that kind of material.
Email law (CAN-SPAM in the US, GDPR and its equivalents elsewhere) sits on top of all of this, so confirm your setup with a lawyer who knows FDA and FTC rules as well as email consent law.
Abandoned cart email examples for a peptide store
Abandoned cart emails are usually the best-earning flow a store runs, and in this category they’re also the easiest place for a claim to slip in, because most templates are written to sell a feeling. Here are the three we’d send, kept short and factual.
- Email 1, about an hour after the cart is left. Show the cart: product name, amount per vial, lot number, price and a link straight back to checkout. No promise about what the product does.
- Email 2, the next day. Answer the questions that actually stop people paying: shipping cost, delivery time to their region and which payment methods you take. Link the COA for the batch in their cart so they can check it before they buy.
- Email 3, on day 3. A short note that the cart is saved, with a real support contact. If you add a discount here, keep it small and occasional. Buyers who learn that a code always arrives stop paying full price.
Most platforms ship cart templates with lines like “your results are waiting” or “don’t break your protocol”, plus stock photos of people. Rewrite all of it: no effect language, no “protocol”, no images of people, just the vial, the specs and the batch. A cart email is advertising matter under the same rule as every other email you send, so it gets read the same way.
Why peptide email marketing matters more than ads
For most ecommerce brands, email sits beside paid ads. For research peptide brands, paid search and social are largely closed, as we covered in whether you can run Google or Meta ads for a peptide brand. That leaves search, communities and your own list. The list is the only one of those you fully control, which is exactly why it’s worth protecting properly.
What we’d do this week
Export everything from your current platform today, including the suppression list, even if nothing is wrong. Check SPF, DKIM and DMARC on your sending domain. Pick two candidate platforms, read their AUPs against the checklist above, and send the written question to both. Then rewrite any flow that mentions use, results or “how to”, because those emails are a liability wherever you send them.
If you’d rather have someone set up the platform, authentication and compliant flows with you, that’s what our peptide email marketing service covers.
FAQ
What should an abandoned cart email for a peptide store say?
What’s in the cart (name, amount per vial, lot, price), a link back to checkout, the shipping and payment details people hesitate over, and the batch COA. Leave out effect language, “protocol” wording and photos of people, because the email is advertising matter just like your product pages.
Does Klaviyo allow peptide brands?
Klaviyo’s acceptable use policy (updated Apr 9, 2026) doesn’t name peptides, but it prohibits products related to prescription medications, pharmaceutical products, medical therapies and telehealth. Enforcement is at Klaviyo’s discretion, and research peptide senders have no public assurance they’re permitted.
Which email platforms accept research peptide sellers?
We couldn’t find any email platform that publicly states it accepts research peptides. Some policies are silent on the category and some, like Omnisend’s, explicitly prohibit drugs for research purposes. Read the current AUP, describe your business honestly in writing, and keep the reply.
Can I use Amazon SES for peptide emails?
AWS’s acceptable use policy has no industry list and prohibits illegal or fraudulent use and spam. Account review is discretionary, and we haven’t seen anything confirming whether SES approves peptide senders in practice, so ask before you build on it.
How do I move my email list after an account ban?
Use your most recent export with consent records and the suppression list, authenticate your sending domain on the new platform, and warm up with your most engaged contacts first. If the ban came without warning and you have no export, that’s the lesson: export weekly from now on.
What can a peptide brand send by email?
Stick to operational and factual content: restocks, new batches with COA links, shipping updates, new SKUs described by specs, and policy changes. Leave out anything about use, dosing, effects or results.

